With extensive experience in oncology, Pritesh Shah will be
responsible for Novocure’s commercial strategy worldwide
ST. HELIER, Jersey--(BUSINESS WIRE)--
Novocure (NASDAQ:NVCR) announced today that Pritesh Shah has been
appointed as Novocure’s Chief Commercial Officer, reporting to
Novocure’s Chief Executive Officer Asaf Danziger. In this role, Mr. Shah
will be responsible for the development and execution of Novocure’s
commercialization strategy worldwide, and for overseeing Novocure’s
international business units.
Mr. Shah joined Novocure in 2012 as the Senior Director of Global
Marketing and progressed through a series of roles of greater
responsibilities within the commercial organization. Most recently, he
acted as Senior Vice President of the Americas. Prior to joining
Novocure, Pritesh had extensive experience in the oncology field,
including roles at Roche, Genentech, Bristol-Myers Squibb, OSI Oncology
and AVEO. Pritesh holds a Doctor of Pharmacy from the University of
Maryland and a master’s degree in Strategic Communication and Leadership
from Seton Hall University.
“Throughout his time here, Pritesh has demonstrated an inclusive, direct
and transparent leadership style that has helped build cohesion and
foster an environment of collaboration,” Mr. Danziger said. “He has
exemplified a passion for developing people and teams while aligning
individuals and teams toward our patient-forward mission. I welcome
Pritesh to our executive team and am eager to see what our team will
accomplish moving forward.”
About Novocure
Novocure is an oncology company developing a profoundly different cancer
treatment utilizing a proprietary therapy called Tumor Treating Fields,
the use of electric fields tuned to specific frequencies to disrupt
solid tumor cancer cell division. Novocure’s commercialized product is
approved for the treatment of adult patients with glioblastoma. Novocure
has ongoing or completed clinical trials investigating Tumor Treating
Fields in brain metastases, non-small cell lung cancer, pancreatic
cancer, ovarian cancer and mesothelioma.
Headquartered in Jersey, Novocure has U.S. operations in Portsmouth, New
Hampshire, Malvern, Pennsylvania and New York City. Additionally, the
company has offices in Germany, Switzerland, Japan and Israel. For
additional information about the company, please visit www.novocure.com
or follow us at www.twitter.com/novocure.
Forward-Looking Statements
In addition to historical facts or statements of current condition, this
press release may contain forward-looking statements. Forward-looking
statements provide Novocure’s current expectations or forecasts of
future events. These may include statements regarding anticipated
scientific progress on its research programs, clinical trial progress,
development of potential products, interpretation of clinical results,
prospects for regulatory approval, manufacturing development and
capabilities, market prospects for its products, coverage, collections
from third-party payers and other statements regarding matters that are
not historical facts. You may identify some of these forward-looking
statements by the use of words in the statements such as “anticipate,”
“estimate,” “expect,” “project,” “intend,” “plan,” “believe” or other
words and terms of similar meaning. Novocure’s performance and financial
results could differ materially from those reflected in these
forward-looking statements due to general financial, economic,
regulatory and political conditions as well as more specific risks and
uncertainties facing Novocure such as those set forth in its Annual
Report on Form 10-K filed on February 22, 2018, with the U.S. Securities
and Exchange Commission. Given these risks and uncertainties, any or all
of these forward-looking statements may prove to be incorrect.
Therefore, you should not rely on any such factors or forward-looking
statements. Furthermore, Novocure does not intend to update publicly any
forward-looking statement, except as required by law. Any
forward-looking statements herein speak only as of the date hereof. The
Private Securities Litigation Reform Act of 1995 permits this discussion.
View source version on businesswire.com:
https://www.businesswire.com/news/home/20180702005307/en/
Media and Investor:
Ashley Cordova, 212-767-7558
acordova@novocure.com
Source: Novocure